Dual inhibition of VEGF and MET provides a significant survival benefit in GBM models, highlighting a potential therapeutic strategy for combating the invasive properties of GBM in patients treated with VEGF inhibitors like bevacizumab. This evidence concerns the gene VEGFA and glioblastoma.